Discovery and synthesis of a potent sulfonamide ETB selective antagonist

Discovery and synthesis of a potent sulfonamide ETB selective antagonist The Discovery of Sulfonamide Endothelin Antagonists and the Development of the Orally Active ETA Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5- isoxazolyl)-1-naphthalenesulfonamide Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 2. Sulfonamide-Based ET_A/ET_B Mixed Antagonists Biphenylsulfonamide Endothelin Receptor Antagonists. 4. Discovery of N-[[2‘-[[(4,5-Dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1‘-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), A Highly Potent and Orally Active ET_A Selective Antagonist Discovery of Ro 48-5695: A potent mixed endothelin receptor antagonist optimized from bosentan Oteromycin: A Novel Antagonist of Endothelin Receptor Discovery of N-Isoxazolyl Biphenylsulfonamides as Potent Dual Angiotensin II and Endothelin A Receptor Antagonists Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity Discovery and Structure-Activity Relationships of Sulfonamide ETA-Selective Antagonists Design, synthesis, and biological evaluation of benzofuran derivatives as ET receptor antagonists